UA97847C2 - Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии - Google Patents
Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессииInfo
- Publication number
- UA97847C2 UA97847C2 UAA201000852A UAA201000852A UA97847C2 UA 97847 C2 UA97847 C2 UA 97847C2 UA A201000852 A UAA201000852 A UA A201000852A UA A201000852 A UAA201000852 A UA A201000852A UA 97847 C2 UA97847 C2 UA 97847C2
- Authority
- UA
- Ukraine
- Prior art keywords
- morpholin
- phenyl
- dimethyl
- aggression
- adhd
- Prior art date
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title abstract 2
- 230000016571 aggressive behavior Effects 0.000 title abstract 2
- 229940127315 Potassium Channel Openers Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- IAAITAGXZWCRTQ-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 IAAITAGXZWCRTQ-UHFFFAOYSA-N 0.000 abstract 1
- JNWPEEJRMRBMPA-UHFFFAOYSA-N 2-cyclopentyl-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 JNWPEEJRMRBMPA-UHFFFAOYSA-N 0.000 abstract 1
- IMOFGKWQMCCNKF-UHFFFAOYSA-N 2-cyclopentyl-n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCC1 IMOFGKWQMCCNKF-UHFFFAOYSA-N 0.000 abstract 1
- SCOOTUMXCXKEAD-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4,6-trimethylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=C(C)C=C1C SCOOTUMXCXKEAD-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- BPFWCATXXHFMHU-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(F)C(NC(=O)CCCCC)=C(F)C=C1N1CCOCC1 BPFWCATXXHFMHU-UHFFFAOYSA-N 0.000 abstract 1
- OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 abstract 1
- DKKUESYXEUWVTR-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C=C1 DKKUESYXEUWVTR-UHFFFAOYSA-N 0.000 abstract 1
- WOVDEFIGDUUBDM-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC)=C(Br)C=C1N1CCOCC1 WOVDEFIGDUUBDM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200701110 | 2007-08-01 | ||
| PCT/DK2008/050191 WO2009015667A1 (en) | 2007-08-01 | 2008-07-31 | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA97847C2 true UA97847C2 (ru) | 2012-03-26 |
Family
ID=39810209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201000852A UA97847C2 (ru) | 2007-08-01 | 2008-07-31 | Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100256145A1 (enExample) |
| EP (1) | EP2185149A1 (enExample) |
| JP (1) | JP2011513196A (enExample) |
| KR (1) | KR20100050502A (enExample) |
| CN (1) | CN101790374A (enExample) |
| AR (1) | AR070513A1 (enExample) |
| AU (1) | AU2008281112A1 (enExample) |
| BR (1) | BRPI0814180A2 (enExample) |
| CA (1) | CA2694887A1 (enExample) |
| CL (1) | CL2008002273A1 (enExample) |
| EA (1) | EA201070189A1 (enExample) |
| MX (1) | MX2010001171A (enExample) |
| NZ (1) | NZ582942A (enExample) |
| TW (1) | TW200920350A (enExample) |
| UA (1) | UA97847C2 (enExample) |
| WO (1) | WO2009015667A1 (enExample) |
| ZA (1) | ZA201000129B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| CA2715760C (en) * | 2008-02-21 | 2017-06-13 | Mitsubishi Tanabe Pharma Corporation | Solid preparation for oral administration of cariprazine hydrochloride |
| US9056845B2 (en) | 2008-07-16 | 2015-06-16 | Richter Gedeon Nyrt. | Pharmaceutical formulations containing dopamine receptor ligands |
| HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| WO2010105189A1 (en) * | 2009-03-12 | 2010-09-16 | The Johns Hopkins University | Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age |
| WO2010105960A1 (en) | 2009-03-17 | 2010-09-23 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
| DE102009013612A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
| TW201041857A (en) * | 2009-05-11 | 2010-12-01 | Lundbeck & Co As H | Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide |
| CA2762528A1 (en) * | 2009-05-29 | 2010-12-02 | Astellas Pharma Inc. | Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder |
| WO2011133661A2 (en) | 2010-04-21 | 2011-10-27 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
| EP2590961A1 (en) | 2010-07-08 | 2013-05-15 | Pfizer Inc | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP2844247A4 (en) * | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| CN103508960B (zh) * | 2012-06-29 | 2017-12-12 | 江苏先声药业有限公司 | 苯并杂环衍生物 |
| CN103508943B (zh) * | 2012-06-29 | 2017-06-09 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
| CN103012381B (zh) * | 2013-01-10 | 2015-01-07 | 山东大学 | 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用 |
| AU2014360743C1 (en) * | 2013-12-02 | 2021-01-28 | Chemocentryx, Inc. | CCR6 compounds |
| BR112017008178A2 (pt) * | 2014-10-24 | 2017-12-19 | Ono Pharmaceutical Co | ativador do canal de kcnq2-5 |
| US10526280B2 (en) | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
| MX2018015251A (es) * | 2016-06-10 | 2019-04-25 | Scifluor Life Sciences Inc | Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado. |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| PT3730487T (pt) | 2016-06-13 | 2022-07-22 | Gilead Sciences Inc | Derivados de azetidina como moduladores de fxr (nr1h4) |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| EP3366683A1 (en) | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
| PL4122464T3 (pl) | 2017-03-28 | 2024-09-16 | Gilead Sciences, Inc. | Kombinacje terapeutyczne do leczenia chorób wątroby |
| US10590067B2 (en) | 2018-02-20 | 2020-03-17 | H. Lundbeck A/S | Alcohol derivatives of carboxamides as Kv7 potassium channel openers |
| JP7121144B2 (ja) | 2018-02-20 | 2022-08-17 | ハー・ルンドベック・アクチエゼルスカベット | Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体 |
| TWI788325B (zh) * | 2018-02-21 | 2023-01-01 | 丹麥商Ｈ 朗德貝克公司 | 作為Ｋｖ７鉀通道開放劑的醇衍生物 |
| US11358930B2 (en) | 2018-04-20 | 2022-06-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Selective potassium channel agonists |
| CN110511220B (zh) * | 2018-05-22 | 2022-04-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 |
| CN108707087B (zh) | 2018-06-29 | 2020-10-16 | 河北医科大学 | 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途 |
| CN108863893A (zh) * | 2018-07-09 | 2018-11-23 | 湖南博隽生物医药有限公司 | 二氢吲哚类衍生物及其在药物中的应用 |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| AR119521A1 (es) | 2019-08-02 | 2021-12-22 | H Lundbeck As | DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7 |
| JOP20220017A1 (ar) | 2019-08-02 | 2023-01-30 | H Lundbeck As | مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7 |
| EP4007571B1 (en) | 2019-08-02 | 2025-06-18 | H. Lundbeck A/S | Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| WO2021092439A1 (en) | 2019-11-08 | 2021-05-14 | Xenon Pharmaceuticals Inc. | Methods of treating depressive disorders |
| KR102643653B1 (ko) * | 2020-11-13 | 2024-03-06 | 기초과학연구원 | 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
| PE20231815A1 (es) | 2021-02-09 | 2023-11-16 | Xenon Pharmaceuticals Inc | Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia |
| CN116535353A (zh) * | 2022-01-25 | 2023-08-04 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的酰胺类化合物及其制备和应用 |
| CN118026880A (zh) * | 2022-11-11 | 2024-05-14 | 华东师范大学 | 芳基酰胺化合物、包含其的药物组合物及其用途 |
| WO2025038930A1 (en) * | 2023-08-17 | 2025-02-20 | Xenon Pharmaceuticals, Inc. | Azepane and pyrrolidine compounds and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN172468B (enExample) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
| US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
| GB9915414D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| AU779034B2 (en) * | 1999-08-04 | 2005-01-06 | Icagen, Inc. | Benzanilides as potassium channel openers |
| US6469042B1 (en) * | 2001-02-20 | 2002-10-22 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators if KCNQ potassium channels |
| US6855829B2 (en) * | 2001-02-20 | 2005-02-15 | Bristol-Myers Squibb Company | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease |
| EP1392644A1 (en) * | 2001-05-31 | 2004-03-03 | Bristol-Myers Squibb Company | Cinnamide derivatives as kcnq potassium channel modulators |
| AU2003294442A1 (en) * | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | 3-heterocyclic benzylamide derivatives as potassium channel openers |
| US6933308B2 (en) * | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| ATE357438T1 (de) * | 2002-12-27 | 2007-04-15 | Lundbeck & Co As H | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems |
| EP1603858A2 (en) * | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| AU2004220424B2 (en) * | 2003-03-14 | 2009-01-22 | H. Lundbeck A/S | Substituted aniline derivatives |
| AU2004222626B2 (en) * | 2003-03-21 | 2010-06-24 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| WO2004096767A1 (en) * | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| TWI349666B (en) * | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
| EP1861394A1 (en) * | 2005-03-03 | 2007-12-05 | H.Lundbeck A/S | Substituted pyridine derivatives |
| BRPI0615631A2 (pt) * | 2005-09-09 | 2011-05-24 | Lundbeck & Co As H | composto, composição farmacêutica, e, uso de uma composição farmacêutica |
| MX2008009655A (es) * | 2006-02-07 | 2008-09-03 | Lundbeck & Co As H | Metodo para tratar o reducir los sintomas de la esquizofrenia. |
| JP2009535370A (ja) * | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
-
2008
- 2008-07-31 UA UAA201000852A patent/UA97847C2/ru unknown
- 2008-07-31 EP EP08773327A patent/EP2185149A1/en not_active Withdrawn
- 2008-07-31 AR ARP080103329A patent/AR070513A1/es not_active Application Discontinuation
- 2008-07-31 WO PCT/DK2008/050191 patent/WO2009015667A1/en not_active Ceased
- 2008-07-31 CA CA2694887A patent/CA2694887A1/en not_active Abandoned
- 2008-07-31 MX MX2010001171A patent/MX2010001171A/es not_active Application Discontinuation
- 2008-07-31 AU AU2008281112A patent/AU2008281112A1/en not_active Abandoned
- 2008-07-31 CN CN200880101135A patent/CN101790374A/zh active Pending
- 2008-07-31 JP JP2010518498A patent/JP2011513196A/ja not_active Ceased
- 2008-07-31 NZ NZ582942A patent/NZ582942A/en not_active IP Right Cessation
- 2008-07-31 KR KR1020107002904A patent/KR20100050502A/ko not_active Withdrawn
- 2008-07-31 US US12/671,505 patent/US20100256145A1/en not_active Abandoned
- 2008-07-31 BR BRPI0814180-0A2A patent/BRPI0814180A2/pt not_active IP Right Cessation
- 2008-07-31 EA EA201070189A patent/EA201070189A1/ru unknown
- 2008-08-01 CL CL2008002273A patent/CL2008002273A1/es unknown
- 2008-08-01 TW TW097129164A patent/TW200920350A/zh unknown
-
2010
- 2010-01-07 ZA ZA2010/00129A patent/ZA201000129B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201070189A1 (ru) | 2010-08-30 |
| US20100256145A1 (en) | 2010-10-07 |
| BRPI0814180A2 (pt) | 2015-01-27 |
| CN101790374A (zh) | 2010-07-28 |
| JP2011513196A (ja) | 2011-04-28 |
| MX2010001171A (es) | 2010-03-01 |
| AR070513A1 (es) | 2010-04-14 |
| CL2008002273A1 (es) | 2009-07-17 |
| ZA201000129B (en) | 2011-04-28 |
| EP2185149A1 (en) | 2010-05-19 |
| NZ582942A (en) | 2011-09-30 |
| AU2008281112A1 (en) | 2009-02-05 |
| TW200920350A (en) | 2009-05-16 |
| CA2694887A1 (en) | 2009-02-05 |
| KR20100050502A (ko) | 2010-05-13 |
| WO2009015667A1 (en) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA97847C2 (ru) | Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии | |
| JP2011513196A5 (enExample) | ||
| PL2044043T5 (pl) | Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych | |
| MX2010003565A (es) | Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina. | |
| GEP20125425B (en) | Biaryl ether urea compounds | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
| TW200745040A (en) | Quinoline derivatives | |
| TW200716111A (en) | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
| UA100501C2 (uk) | Карбоксамідні сполуки і їх застосування як інгібіторів кальпаїнів | |
| MA32627B1 (fr) | Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase | |
| DE602005018981D1 (de) | Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus | |
| MXPA06012640A (es) | Compuestos de morfolina. | |
| NO20081685L (no) | Fremgangsmate for fremstilling oksazolidin-beskyttelse aminodolforbindelser anvendbare som mellomprodukter for Florfenicol | |
| TW200732313A (en) | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
| TW200700392A (en) | Novel compounds | |
| CY1109975T1 (el) | Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
| TW200728302A (en) | Chemical compounds VI | |
| SI1701940T1 (sl) | 2-(1h-indolilsulfanil)-benzil aminski derivati kot ssri | |
| TW200700416A (en) | 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | |
| MX2011011490A (es) | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. | |
| MY148880A (en) | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression | |
| TW200745085A (en) | Quinoline derivatives | |
| SE0402284D0 (sv) | New heterocyclic amides | |
| EP1928235A4 (en) | COMPOSITION AND METHOD FOR USE IN DISEASES WITH CARTILAGE PARTICIPATION |